Navigation Links
Phase 3 Topical Drug for Raynaud's Disease Available for Licensing/Acquisition at the J.P. Morgan Conference
Date:12/13/2012

BOTHELL, Wash., Dec. 13, 2012 /PRNewswire-iReach/ -- MediQuest Therapeutics Inc., a specialty pharmaceutical company focused on inflammatory skin diseases and conditions, today announced that they will be conducting partnering/M&A meetings at the J.P. Morgan 31st Annual Healthcare Conference between January 7th and 10th in San Francisco, regarding its Phase 3 topical formulation, VASCANA, designed to treat Raynaud's Disease, an unmet medical need. MediQuest is also selling/licensing the remainder of its topical assets including a skin lightener, ready for commercialization.  Its topical/non-systemic Onychomycosis drug was out-licensed in August 2012.

(Photo: http://photos.prnewswire.com/prnh/20121213/CG29278)

MediQuest's VASCANA has a Special Protocol Assessment granted by the Federal Food & Drug Administration for a single Phase 3 study involving approximately 150 patients that suffer from moderate to severe symptoms of Raynaud's Syndrome.  VASCANA has a strong safety profile and an extensive intellectual property portfolio with issued patents that run to 2026.   The peak sales in the United States is estimated at about $250 million, as well as similar markets in EU and Asia, with low cost of goods, supported by 2-years of stability data.

Any company interested in learning more about VASCANA can arrange to meet with MediQuest at the J.P. Morgan conference through the below contact information.  

About Raynaud's Disease
An estimated 9-11 million people in the United States suffer from Raynaud's Disease, 2.1 million of which have been diagnosed and are seeking medical treatment. Raynaud's patients can experience severe pain associated with chronic vasospasm episodes in their hands, feet and other extremities.

About MediQuest Therapeutics, Inc.
MediQuest Therapeutics is a specialty pharmaceutical company using its proprie
'/>"/>

SOURCE MediQuest Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
2. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
3. Insero Health Completes Phase I Trial of Novel Therapy in Patients With Drug Resistant Epilepsy
4. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
5. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
6. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
7. uniQure Initiates Phase I in Acute Intermittent Porphyria
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
10. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
11. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... 11, 2011 Conatus Pharmaceuticals Inc. today announced the ... private placement financing.  This financing was led by new ... participation by existing investors; Aberdare Ventures, Advent Venture Partners, ... Fund.  Conatus will use the proceeds to advance the ...
... 2011 Stryker Corporation,s (NYSE: SYK ) ... 510(k) clearance for its MDM X3 Modular Dual Mobility ... to the company,s portfolio of next-generation technologies designed to ... and address a broader patient population, including both primary ...
Cached Medicine Technology:Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing 2Stryker Receives FDA 510(k) Clearance to Market Modular Dual Mobility Acetabular (Hip) System 2Stryker Receives FDA 510(k) Clearance to Market Modular Dual Mobility Acetabular (Hip) System 3
(Date:4/17/2014)... international research team led by Cesar A. Arias, M.D., ... at Houston (UTHealth) has identified a new superbug that ... report appeared in the April 17 issue of ... new superbug is part of a class of highly-resistant ... MRSA, which is a major cause of hospital and ...
(Date:4/17/2014)... is less than 40 years away from a food ... governments, according to a top scientist at the U.S. ... human history, food production will be limited on a ... energy," said Dr. Fred Davies, senior science advisor for ... become as politically destabilizing by 2050 as energy issues ...
(Date:4/17/2014)... its status as the leading weapon against the deadly ... with new research indicating it simply needs to be ... of the cheap anti-malarial drug chloroquine in treating and ... more than half a million people each year around ... developed resistance to chloroquine, but research carried out at ...
(Date:4/16/2014)... SAN ANTONIO, Texas (April 16, 2014) A team that ... of Texas Health Science Center at San Antonio, Johns Hopkins ... protein that helps a common fungus to infect the body. ... infections, diaper rashes and oral thrush, and is the most ...
(Date:4/15/2014)... Scientists have solved a decades-old medical mystery and in the ... fungal infections, which kill about 1.5 million people a year. The ... an antifungal drug that has been in use for more than ... human cells as it is to the microbes it attacks. , ...
Breaking Medicine News(10 mins):Health News:New MRSA superbug emerges in Brazil 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3
... EAGAN, Minn., Feb. 9 Blue Cross and Blue Shield of Minnesota ... manager of the largest database of vendored disease management programs. The awards ... reducing adverse health events for its members. Blue Cross, disease management efforts ... diabetes , ...
... Equips Participants with Tools to Live Healthy, Active LivesCLEVELAND, ... Clinic has consistently sought to shift the national focus ... part of this commitment , Cleveland Clinic has ... helps reverse and decrease the effects of several common ...
... boosts well-being, study suggests, , , MONDAY, Feb. 9 (HealthDay ... buy happiness, purchasing life experiences instead of material possessions ... a study that asked more than 150 older college ... them happy, researchers found that people were more satisfied ...
... the Top Achievements in 50 Years of Women,s Health RARITAN, ... globulin product, celebrates its 40th year in the marketplace helping ... Newborn (HDN). In 1968, a new mother at Holy ... initial recipient of the world,s first injectable treatment to prevent ...
... intended to prevent HIV infection in women has demonstrated ... in Africa and the United States. Findings of the ... Allergy and Infectious Diseases (NIAID), part of the NIH, ... Opportunistic Infections in Montreal. , The study investigators ...
... Cancer Research Center have discovered a mechanism in liver metabolism ... in severe metabolic disorders. Mice suffering from metabolic syndrome or ... called LSR in the liver, as reported by researchers headed ... As a result, only small amounts of fat are ...
Cached Medicine News:Health News:Blue Cross Receives Disease Management Awards 2Health News:Blue Cross Receives Disease Management Awards 3Health News:Cleveland Clinic Launches Ground-Breaking Wellness Program To Reverse Effects of Common Chronic Diseases 2Health News:Cleveland Clinic Launches Ground-Breaking Wellness Program To Reverse Effects of Common Chronic Diseases 3Health News:Cleveland Clinic Launches Ground-Breaking Wellness Program To Reverse Effects of Common Chronic Diseases 4Health News:Experiences Bring More Joy Than Possessions Do 2Health News:Experiences Bring More Joy Than Possessions Do 3Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 2Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 3Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 4Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 5Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 6Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 7Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 8Health News:Landmark Rh Immune Globulin Celebrates 40 Years of Saving Babies' Lives 9Health News:Anti-HIV gel shows promise in large-scale study in women 2Health News:Anti-HIV gel shows promise in large-scale study in women 3Health News:Anti-HIV gel shows promise in large-scale study in women 4Health News:Pathologically elevated blood fat levels in obesity: Researchers discover molecular causes 2
... CDI creates a smoother fit in the ... patient. The padded continuous hook and eye ... and the extra strong, yet very thin ... as a reinforced open crotch, gripper lace ...
This compression garment can be used immediatlely following Abdominoplasty, Tram Flap, Abdominal Liposuction, Lipoplasty, Suction Lipectomy, Stomach Liposuction, Liposculpture and Tummy Tuck procedur...
This compression garment can be used immediatlely following Abdominoplasty, Tram Flap, Abdominal Liposuction, Lipoplasty, Suction Lipectomy, Stomach Liposuction, Liposculpture and Tummy Tuck procedur...
Short Girdle, Mid-thigh, Front Closure...
Medicine Products: